The principal investigator has developed the evolution of his research in the area of the cellular pharmacology of anticancer drugs emerging from a basic background in membrane transport to a more comprehensive approach to study of the interaction between anticancer drugs and the intact cell. This is an approach that distinguishes among membrane transport, drug metabolism, interactions between drugs, metabolites and intracellular targets and the role of these various interactions as determinants of drug cytotoxicity, selectivity and resistance. A major emphasis of the investigator's work has been in the area of 4-amino antifolate pharmacology, with contributions in the area of membrane transport, the nature of the interaction between methotrexate and dihydrofolate reductase in cells and, more recently, comprehensive studies to explore the polyglutamylation of methotrexate, its 7-hydroxy catabolite and aminopterin. This research has been done within the context of interactions and collaborations with faculty involved in a basic membrane biology research and research training program. This has supported basic studies in membrane transport, the application of network thermodynamic modeling to these studies and provides collaborative support for some of the proposed studies. The applicant proposes to continue extensive studies to further explore polyglutamylation of 4-amino antifolates and to assess the cellular and sub-cellular effects of monoglutamyl and polyglutamyl 4-amino antifolates on metabolism of exogenously provided and endogenous tetrahydrofolate cofactors. Other studies will explore the mechanisms of membrane transport of 4-amino folates and the natural tetrahydrofolate cofactors and how intracellular folyl or antifolyl polyglutamates affect these processes. Two new initiatives are proposed. First, studies will assess the effects of 4-amino antifolates on the functional properties of renal tubular epithelial cell monolayers to explore on a cellular level early functional deficits that may herald frank renal cellular damage. Second, other studies will evaluate the functional properties of membrane vesicles obtained from pleiotropic drug resistant cells to confirm whether there is a transport defect in these cells that accounts for drug resistance and to define the changes in the physical properties of these vesicles that may be the basis for this phenomenon.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
1R35CA039807-01
Application #
3479062
Study Section
(SRC)
Project Start
1985-09-11
Project End
1992-08-31
Budget Start
1985-09-11
Budget End
1986-08-31
Support Year
1
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Sharina, I G; Zhao, R; Wang, Y et al. (2001) Mutational analysis of the functional role of conserved arginine and lysine residues in transmembrane domains of the murine reduced folate carrier. Mol Pharmacol 59:1022-8
Zhao, R; Gao, F; Goldman, I D (2001) Molecular cloning of human thiamin pyrophosphokinase. Biochim Biophys Acta 1517:320-2
Zhao, R; Russell, R G; Wang, Y et al. (2001) Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 276:10224-8
Rajgopal, A; Sierra, E E; Zhao, R et al. (2001) Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol Cell Physiol 281:C1579-86
Wang, Y; Zhao, R; Russell, R G et al. (2001) Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim Biophys Acta 1513:49-54
Zhao, R; Gao, F; Wang, Y et al. (2001) Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 276:1114-8
Zhao, R; Gao, F; Goldman, I D (2001) Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 61:857-65
Zhao, R; Gao, F; Liu, L et al. (2000) The reduced folate carrier in L1210 murine leukemia cells is a 58-kDa protein. Biochim Biophys Acta 1466:10-Jul
Zhao, R; Titus, S; Gao, F et al. (2000) Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 275:26599-606
Zhao, R; Gao, F; Babani, S et al. (2000) Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier. Clin Cancer Res 6:3304-11

Showing the most recent 10 out of 49 publications